HCW Biologics Inc.

HCW Biologics Inc. announced the settlement and extinguishment of $2.8 million in disputed accounts payable during the three months ending June 30, 2026. This includes the resolution of a lawsuit and a $1.1 million mechanics' lien with B&I Contractors, Inc. Additionally, the company fully settled its obligations with EirGenix, Inc., reducing manufacturing costs from $1.7 million to $1.2 million through a settlement agreement.

HCW Biologics Inc. announced that it has regained compliance with Nasdaq's Bid Price Rule, Listing Rule 5550(a)(2), as determined by the Nasdaq Hearings Panel on June 29, 2026. The company will be under a mandatory monitoring period until June 17, 2027. To maintain long-term compliance, HCW Biologics will implement a one-for-six reverse stock split on June 30, 2026.

HCW Biologics Inc. announced a 1-for-6 reverse stock split, effective June 30, 2026, to maintain compliance with Nasdaq's $1.00 minimum bid price requirement. The Board of Directors approved the split after stockholders granted the authority, aiming to prevent automatic delisting. The reverse split will reduce the number of outstanding shares and adjust options and warrants proportionately, with fractional shares rounded up.

HCW Biologics Inc. announced its Board of Directors approved a 1-for-6 reverse stock split of its common stock, effective June 30, 2026. The split is intended to ensure ongoing compliance with the Nasdaq Bid Price Rule and other requirements from a Nasdaq Hearings Panel, which had mandated the stock trade above $1.00 for 20 days prior to July 29, 2026. The company's common stock completed 28 consecutive trading days above $1.00 as of June 25, 2026, but the split is still deemed necessary to maintain compliance. The number of outstanding shares will decrease from 9,581,079 to approximately 1,596,849.

HCW Biologics Inc. filed an S-1 registration statement amendment on June 18, 2026. The filing primarily serves to update the exhibit index, incorporating various agreements and documents by reference or furnishing them. The remainder of the registration statement is unchanged.

HCW Biologics announced positive preliminary human data from the first two dose cohorts of its dose-escalating Phase 1 clinical trial for HCW9302, an IL-2 based fusion immunotherapeutic, in patients with alopecia areata. All three participants in the second dose cohort (3 micrograms/kg) showed preliminary indications of improvement in Severity of Alopecia Tool (SALT) scores, with a >=25% reduction compared to baseline. The treatment was well tolerated, with no dose-limiting toxicities or significant IL-2-treatment-related adverse effects, including no reported incidence of capillary leak or cytokine release syndrome. The company aims to establish the Recommended Phase 2 Dose by year-end 2026 and plans to explore multi-dose studies for alopecia areata and other autoimmune diseases.

HCW Biologics announced positive preliminary human data from the first two dose cohorts of its Phase 1 clinical trial for HCW9302 in patients with alopecia areata. All three participants in the second dose cohort (3 micrograms/kg) showed preliminary indications of improvement with a ">=25%" reduction in SALT scores. The IL-2 based fusion immunotherapeutic was well tolerated, with no dose-limiting toxicities or significant adverse effects. The company projects to establish the Recommended Phase 2 Dose by year-end 2026 and plans to explore multi-dose studies and other autoimmune indications.

HCW Biologics Inc. has filed an S-1 registration statement for the resale of up to 5,693,950 shares of common stock by selling stockholders. This includes shares from a recent PIPE transaction and warrants. The company also received a Nasdaq exception to regain compliance with the minimum bid price rule by July 29, 2026, and elected to terminate a license agreement with Wugen Inc.

HCW Biologics Inc. has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the minimum $1 bid price rule. The company must achieve a bid price of $1 or more for 20 consecutive trading days by July 29, 2026. This extension comes after the company failed to meet the bid price requirement and was not given a standard 180-day grace period due to a prior reverse stock split. The Panel has imposed strict conditions, including immediate delisting for any further bid price deficiency before September 22, 2026.

HCW Biologics Inc. announced it has exercised its option to terminate the exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to its molecules HCW9201 and HCW9206. This strategic move allows HCW Biologics to regain full commercial rights to these two compounds at no cost, while retaining the initial license fee and 2.2 million shares of Wugen common stock. The company aims to commercialize these reagents, which have shown potential to improve CAR-T cell therapy manufacturing and efficacy, through new partnerships in the fast-growing CAR-T immunotherapy market.